Contents
The first shipment of the COVID-19 vaccine from Johnson & Johnson reached Poland – it amounts to 120. doses. Thus, four preparations are already available in Poland: Pfziera, Moderny, AstraZeneki and J&J. Who is the Johnson & Johnson vaccine for, what is the effectiveness, what technology is used – here are the most important information.
- The J&J vaccine is the only vaccine that requires only one dose
- The effectiveness was estimated at about 66 percent.
- There have been reports of blood clots following the administration of this vaccine in the USA. The case is being investigated by the European Medicines Agency
- You can find out more about coronavirus vaccinations on the TvoiLokony home page
Johnson & Johnson vaccine – for whom?
The vaccine called COVID-19 Vaccine Janssen is the fourth preparation approved in the European Union, its deliveries to the Member States started on Monday. The Johnson & Johnson vaccine is the only vaccine that requires only one dose. The vaccines from Pfizer / BioNTech, Moderna and AstraZeneca are two-dose.
The preparation, developed by Janssen Pharmaceutica NV, a company from the pharmaceutical division of Johnson & Johnson, will be in Poland – as announced by the government – used, among others in people who cannot get to the vaccination points on their own.
COVID-19 Vaccine Janssen is given to people over 18 years of age by intramuscular injection only, with the upper arm being the preferred site. According to the Summary of Product Characteristics, protection begins approximately 14 days after vaccination.
The vaccine causes the immune system to produce antibodies and specialized white blood cells to work against the virus, thereby providing protection against COVID-19.
Johnson & Johnson vaccine – storage
The preparation is distributed in vials containing five doses of 0,5 ml. The glass vial has a rubber stopper, aluminum cap and a blue plastic cap.
The unopened vial is valid for two years when stored at -25 degrees C to -15 degrees C. After removal from the freezer, the unopened vaccine may be stored in a refrigerator at 2 degrees C to 8 degrees C, in a place protected from light, for a single period of up to three months. At temperatures between 9 degrees C and 25 degrees C, the unopened COVID-19 Vaccine Janssen vaccine is stable for 12 hours.
After the vial is punctured for the first time, the product can be stored at 2-8 degrees C for a maximum of 6 hours or at room temperature (maximum 25 degrees C) for up to 3 hours after being consumed.
Johnson & Johnson vaccine – manufacturing technology
The vaccine is based on the replication-deficient adenovirus, Ad26. It is the carrier of the genetic material by which the cells of the vaccinated person begin to produce the spike protein (spike protein, S protein) of the SARS-CoV-2 virus that causes COVID-19. By reacting to the protein of the virus, the body builds up immunity.
Johnson & Johnson vaccine – effectiveness
The preparation of the Johnson & Johnson concern has an efficiency of approx. 66%.
Let us recall that the effectiveness of the Pfizer and Moderna vaccines was estimated at 95%, and AstraZeneki at about 76%.
Johnson & Johnson vaccine – blood clots
On Tuesday, the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) recommended that vaccination with the preparation be suspended in the US due to the occurrence of six cases of rare blood clots among 6,8 million vaccinated people.
Read more: USA: Call for Johnson & Johnson Vaccine Suspension. More cases of thrombosis
Following the signals, last week, the European Medicines Agency (EMA) started work to assess reported embolic and thrombotic events in people who received the Janssen COVID-19 vaccine.
The President of the Office for Registration of Medicinal Products in an interview with PAP said on Tuesday that it is currently unclear whether there is a causal link between vaccination with the COVID-19 vaccine and the aforementioned diseases. He said there would be a discussion on the matter at the EMA on Wednesday morning.
Previously, cases of thrombosis with thrombocytopenia also occurred in people vaccinated with AstraZeneka. Ultimately, after analyzing these cases, the EMA gave the opinion in early April that these are very rare cases, and that the benefits of AstraZeneki in preventing COVID-19 outweigh the risk of side effects.
The EU placed an order for 200 million doses of this vaccine, with an option for an additional 200 million doses. In mid-March, the President of the European Commission, Ursula von der Leyen, announced that EU countries should receive in the second quarter of this year. approximately 55 million doses of the preparation.
Author: Katarzyna Lechowicz-Dyl / PAP
This may interest you:
- What is the risk of infection from vaccinated and healed?
- They got vaccinated and fell ill. How many such cases in Poland?
- Are there groups of patients who should not be vaccinated with AstraZeneka?
The content of the medTvoiLokony website is intended to improve, not replace, the contact between the Website User and their doctor. The website is intended for informational and educational purposes only. Before following the specialist knowledge, in particular medical advice, contained on our Website, you must consult a doctor. The Administrator does not bear any consequences resulting from the use of information contained on the Website. Do you need a medical consultation or an e-prescription? Go to halodoctor.pl, where you will get online help – quickly, safely and without leaving your home.Now you can use e-consultation also free of charge under the National Health Fund.